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Abstract

Osteoblastogenesis is an essential part of the bone healing process. Insulin has been
shown to improve bone healing in both normal and diabetic bone healing models. In addition,
insulin mimetic compounds such as Zinc chloride (ZnCl2) and Vanadyl acetylacetonate (VAC)
have also been shown to improve bone healing in these models as well. The purpose of this study
was to determine the effects of vanadium compounds VAC and Vanadium (II) sulfate (VSO4) in
osteoblast proliferation and function. In addition the mechanisms by which growth and function
are facilitated by these Vanadium compounds were also evaluated. In this study, we determined
if treatment with VAC and VSO4 could induce osteoblast proliferation in the MC3T3-E1 mouse
cell line. MC3T3-E1 cells were treated with 50ug/ml insulin, 50ug/ml ascorbic acid, 0µM,
5µM, 10µM, 15µM, 25µM, 50µM, or 100µM, of VAC or VSO4 and harvested at the following
time points 6hrs, 24hrs, 4 days, 7 days, 10 days, 14 days, 17 days, and 21 days. MC3T3-E1
proliferation, function, and mechanisms of growth were evaluated via MTT Assays, Alizarin Red
staining/Alcian blue staining, and immunoblotting respectively. Our results demonstrate that
both VAC and VSO4 are capable of inducing MC3T3-E1 proliferation as shown by the MTT
assay. Treatment with VAC and VSO4 can also induce calcium and proteoglycan deposition as
shown by Alizarin red and Alcian blue staining in MC3T3-E1 cells. VAC and VSO4 treatment
also increased activation of protein kinase B (Akt) to its activated form p-Akt over time. Our
results coincide with other studies that show that Vanadium compounds can stimulate
osteoblastogenesis. Also that this is achieved through utilization of insulin pathways and
promoting proper function of osteoblast cells. Our data suggests that VAC and VSO4 may be
useful as medications for promoting bone growth during the fracture healing process.
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Introduction

Bone healing is a complex process that involves regulation by several mechanical,
genetic, and biological factors, which can take several weeks to several years to heal depending
on the size of the injury [1]. While bone healing occurs naturally within healthy individuals,
there are still several factors which can slow the rate of healing including excessive/prolonged
inflammation or the stability of the fracture [3]. Additionally, there is a significant portion of the
population that suffers from impaired bone healing, especially those with comorbidities such as
diabetes mellitus [2]. Current medications focus on accelerating the healing process in both
cartilage and bone cells for poor or lengthy fracture healing [4]. The mechanisms which different
drugs utilize to facilitate bone fracture healing are not fully understood, as such preliminary
studies on emerging drugs are often performed on bone and cartilage tissues in-vitro [5].
However as the mechanisms behind which ascorbic acid (AA) and the insulin pathway, (utilizing
FOXO1 as a transcription factor to control gluconeogenesis and glycogenolysis), promote bone
healing are well understood [6, 7] research on insulin mimetics which utilize the same pathway
to insulin itself may lead to the development of medications with well understood growth
mechanisms. This research focused on the bone healing properties of the small molecule insulin
mimetic Vanadium and two of its compounds vanadyl acetyl acetonate (VAC) and vanadium (II)
sulfate (VSO4).
Fracture repair requires proliferation and differentiation of several tissue types in a
distinct sequence [3]. There are five major stages involved in fracture healing inflammation, soft
tissue formation, hard tissue formation, and remodeling. After physical trauma has occurred a
hematoma is generated which consists of cells from both peripheral/intramedullary blood, and
bone marrow cells, which initiate an inflammatory response [8]. The proinflammatory response
2

involves macrophages and the secretion of tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1),
IL-6, IL-11 and IL-18, which promote angiogenesis and recruit inflammatory cells. TNF-α
promotes the recruitment of mesenchymal stem cells (MSCs) with chondrogenic and osteogenic
potential [8]. After the formation of the primary hematoma, a fibrin-rich granulation tissue
forms, within this tissue endochondral formation occurs in between the external to periosteal
sites and the ends of the fracture. This cartilaginous tissue forms a soft callus in order to
stabilize the structure of the healing bone. However the soft callus must be reabsorbed and a new
hard bony callus will take its place through the process of endochondral ossification. As the
chondrocytes within the soft callus grow, they become hypertrophic, calcifying the extracellular
matrix. This calcification utilizes the mitochondria and accumulates calcium-containing granules
created within the hypoxic environment of the fracture [8]. Once the calcium granules have
integrated into the cytoplasm of soft callus chondrocytes, they are transported into the
extracellular matrix where they precipitate with phosphate to create mineral deposits. These
deposits form the hard callus, and while the hard callus provides stability, however, it does not
completely restore the biomechanical function of bone. For complete functionality to return, the
bone must be remodeled. IL-1 and TNF-α initiate a signaling cascade to recruit osteoclasts which
reabsorb excess bone from the hard callus and osteoblast cause lamellar bone deposition to
stabilize the structure of the bone [8].
Certain drugs can affect the proliferation of early callus and others influence the
differentiation of osteoblasts or chondrocytes, the sensitivity to mechanical input, or the
formation of capillaries [4]. Noninvasive methods of fracture healing treatment, like systemic
injections with levodopa (L-dopa) or Teriparatide, have been shown to increase the speed of
healing, the latter is utilized bone fractures caused due to osteoporosis [9, 10]. However, the

3

mechanisms by which such drugs affect bone and cartilage signaling pathways remain largely
unknown. Bone is one of few tissues types that is capable of healing without forming any
fibrous scar tissue. Despite this strong regenerative ability, the healing process can fail leading to
fractures healing in improper anatomical positions, as well as delayed healing, and the
development of non-unions or pseudoarthrosis [11]. When bone needs to regenerate
mesenchymal stem cells (MSCs) capable of differentiating into osteogenic cells need to be
recruited and proliferate. The origin of these cells is not completely understood, recent data
suggests that they are derived from surrounding bone marrow and soft tissue, as well as systemic
recruitment in response to trauma at the injury site [12]. Chemotactic factors released at the site
of the bone defect may play an essential role in MSC homing and recruitment, thus far it is
known that MSCs express 19 different chemokine receptors [13]. Of these CXCR4 and its ligand
(CXCL12 or stromal-derived factor 1; SDF1) are the most widely investigated mediators in MSC
recruitment. Under normal conditions, Hypoxia-inducible factor 1-alpha (HIF-1α) is
hydroxylated by the activity of prolyl hydroxylase domain protein 2 (PHD2). This leads to HIF1α binding to the von Hippel-Lindau protein (VHL) as well as proteasomal and ubiquitination
(Ub) degradation [13]. Under hypoxia conditions, because of a reduction in PHD2 activity, HIF1α levels stabilize and form a complex with HIF-1β. Then HIF-1α binds to the hypoxiaresponsive element (HRE) on the promoter of the CXCL12 gene. This is done through the
assistance of transcriptional coactivating CREB-binding protein (CBP). Once the promotor
causes the upregulation of CXCL12 at the site of the fracture, MSCs from the blood migrate to
the site of injury due to the CXCR4 on the MSCs [13]. In addition, while bone morphogenic
protein-2 (BMP-2) is important for bone repair, it along with BMP-7 seem to play an important
role in recruiting progenitor cells [14]. In a study conducted by Bais et al in vitro studies on
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bone marrow sC57 BL/6J (B6) mice cells displayed that exogenously added BMP7 rescued the
expression of osterix, an osteoblast-specific transcription factor which induces differentiation of
preosteoblasts into mature osteoblasts as well as enhanced the expression of Sox9 (a
transcription factor utilized in chondrocyte development), but had no effect on the expression of
Runt-related transcription factor 2 (Runx2, a transcription factor utilized in osteoblast
differentiation) [14]. While it only partially recovered the development of mineral deposition in
the cultures. On the other hand, the exogenous addition of BMP2 rescued both Runx2 and osterix
expression, did not enhance the expression of Sox9, but fully recovered the inhibition of mineral
deposition in the cultures. In this same study BMP7 rescue in BMP2 shRNA-treated cultures
increased the expression of Sox9 which suggests that BMP7 plays a role in expanding the
progenitor cell population. Also, the differences in the effects of BMP2 and BMP7 on Runx2
expression could affect the progenitor cell population since increased Runx2 expression induces
decreased proliferation and terminal commitment of the osteoprogenitors cells to their terminal
state of differentiation [14].
In in-vitro studies, the use of primary cells is advantageous in that they can accurately
mimic the reaction of osteoblasts within a model organism’s body to various stimuli. However,
there are disadvantages to using these cells such as limited cell proliferation, possible damage to
the donor site during collection, and a chance of genetic changes during cell culture cultivation
[15]. As such utilization of mouse derived cell line of osteoblast precursor cells, MC3T3 cells, is
common practice in osteogenic studies. A derivative of this cell line, MC3T3-E1 sub-cell line, is
considered one of the most useful and convenient physiological systems for the study of
osteoblast transcriptional control due to its ability to consistently differentiate into osteoblasts
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using simple monolayer cell culturing methods [16, 17]. These cells are capable of proliferating
for numerous divisions and can be frozen down for convenient storage [16].
It the 1500s Vitamin C deficiencies were found to lead to conditions such as scurvy which
are associated with symptoms including bone pain and impaired bone healing [17]. These
characteristics correlate most closely to Vitamin C’s reduced form, ascorbic acid (AA), and its
ability to affect osteoblast growth. Osteoblasts treated with AA exhibit increased levels of
transforming growth factor (TGF)-β, osteopontin (OPN), and estrogen receptor (ER)-α, all of
which are important regulators in the formation of bone. The main sources of TGF-β utilized in
the bone healing process are almost all cells involved in the inflammation response, like
macrophages, blood platelets responding to the fracture site, and the surrounding ECM releasing
TGF-β after an injury leading to tissue ischaemia a change in pH near the fracture site [18]. TGFβ has a chemotactic ability, which allows for the recruitment of MSC, immune cells such as Tcells, macrophages, and monocytes, osteoprogenitor cells, chondroprogenitor cells, and
fibroblasts [18]. TGF-β regulates levels of the Ras homolog A (RhoA), a small GTPase protein,
which is involved in cytoskeleton regulation, mostly actin stress fibers formation and actomyosin
contractility. Control of cellular cytoskeletons is essential for the recruitment of different cell
types to the site of a fracture as it controls the movement of cells towards the site [19]. OPN
binds to several integrins such as α4β1, α5, α9β1, αvβ3, αvβ5, and αvβ1. OPN-αvβ3 binding
onto the surface of osteoclasts causes integrin clustering, which induces intracellular signaling
through the phosphorylation of protein tyrosine kinase 2 (PYK2), this allows for the binding of
proto-oncogene tyrosine-protein kinase (Src) through its SH2 domain. The binding of Src-PYK2
induces phosphorylation of PYK2 at other sites, this amplifies the signals activating cellular
functions like the osteoclast cell adhesion to mineralized bone [20]. The most abundant estrogen
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17β-estradiol (E2), is activated by estrogen receptor (ER) alpha (ERα). Through ERα activation,
E2 promotes the transcription of Fas Ligand (FasL) in osteoblasts. FasL is cleaved from the cell
surface by the enzyme Stromelysin 1 (MMP3) and induces osteoclast apoptosis. For bone
formation to occur, osteoblast activity needs be at a higher level than osteoclast activity [21]. In
another study, conducted with ovariectomized mice, AA was found to prevent the loss of
osteoblast differentiation markers (Runx2, BMP-2, osteocalcin, Osterix), reduce bone loss, and
stimulate bone growth. As a result, AA is typically used as a positive control for osteoblast
research studies (7, 22, 23).
During bone repair a bony cartilaginous callus must form in order to bridge the gap(s)
created by the bone fracture [4]. Fracture studies have shown that by applying insulin locally to
healing tissue, callus cartilage formation is greatly enhanced in both normal and diabetic rat
models. In a study conducted by Gandhi et al. an intramedullary insulin delivery system was
utilized in a diabetic BB Wistar femur fracture model in order to explore the effects of local
insulin administration on bone healing. It was observed that insulin delivery at the fracture site
normalized the early (chondrogenesis) and late (soft callus formation, hard callus formation, and
mechanical strength) parameters of diabetic fracture healing. The results indicate the importance
of insulin in mediating fracture healing, and that decreased systemic insulin levels in diabetic
models leads to a decrease in insulin levels at a fracture site as well as an increase in the overall
healing time of a diabetic fracture [7]. Just as Vitamin C has several vital roles throughout the
body, insulin plays a key role in several biological processes, including bone formation. When
insulin binds to its receptor, it activates downstream Mitogen-activated protein kinases
(MAPKs), which can promote bone growth through osteoblast commitment and differentiation.
Of the three classic MAPKs, p38 and ERK are the most important in determining the shape of
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the skeleton. Also, p38 and ERK are essential throughout the osteoblastic commitment process,
from a mesenchymal progenitor cell to a fully operational anabolic bone cell [24]. In addition,
insulin is capable of inducing an intracellular cascade which leads to the phosphorylation of
insulin receptor substrate 1 (IRS1) and IRS2, as well as the activation of phosphatidylinositide-3kinase (PI3K). PI3K then activates protein kinase B (Akt), making it phosphor (p)-Akt, which in
turn phosphorylates and deactivates FOXO1. FOXO1 is a transcription factor which is capable
of inducing genes that control gluconeogenesis and glycogenolysis. Dysregulated FOXO1
expression can lead to hyperglycemia [25] and is related to diabetic bone complications
including poor healing [25, 26].
Dysregulated FOXO1 expression and poor bone healing is correlated with a reduction of
IRS1/IRS2 activity and diminished PI3K activation [27]. Conversely, MAP kinase activity is
increased in these cases [27]. IRS1/IRS2 need to be functioning properly in order to activate
PI3K and Akt. Moreover, reductions in insulin signaling leads to lower levels of Akt activation,
higher levels of FOXO1 activation, and hyperglycemia [27]. Hyperglycemia induces prolonged
inflammation, the formation of advanced glycation end-products (AGEs), and reactive oxygen
species (ROS). This coupled with lower insulin signaling leads to an increase in the formation of
osteoclasts, (which are responsible for bone reabsorption) [27]. While osteoclast proliferation is
increased, the dysregulation of AGEs and ROS can lead to the reduction of Runx2, BMPs, and
Fra1, and thus a decrease in osteoblast proliferation [27]. While local administration of insulin is
capable of inducing osteoblast proliferation, it requires an administration method that would
prevent hypoglycemia. As such, research has been conducted which utilizes insulin mimetic
small molecules such as vanadyl acetylacetonate (VAC) to promote bone healing. Insulin
mimetics are able to stimulate the phosphorylation of both glycogen synthase kinase 3 (GSK-3)
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and Akt [28, 29] and are capable of inhibiting protein tyrosine phosphatase (PTPs) [30]. PTPs
like the dual-specificity phosphatase MAPK phosphatase-1 (MKP-1) and SHP-2, a cytosolic Src
homology 2 (SH2) domain-containing PTP, affect osteoclast formation and differentiation by
functioning as a counteracting enzyme activity to protein tyrosine kinases (PTK)-mediated
phosphorylation of important phospho (PY)-containing signaling proteins. For instance, MAPKs
are dephosphorylated and inactivated by MAPK phosphatase (MKP-1), which leads to
suppression of macrophage colony-stimulating factor (m-CSF) and receptor activator of NFκB
ligand (RANKL)-mediated differentiation as well as proliferation of osteoclast progenitor cells
[30]. On the other hand, SHP-2 is recruited to the m-CSF receptor (c-Fms) and other receptor
PTKs though the Growth factor receptor-bound protein 2 (Grb2)-associated binding family of
proteins to dephosphorylate and inhibit the Ras GTPase activating protein (RasGAP) activity
responsible for suppressing Ras function [30]. This induces extension of Extracellular Signalregulated Kinase (Erk1/2)- activation and leads to enhanced m-CSF- and RANKL-mediated
proliferation and differentiation of osteoclast precursor cells [30].
In this study a small molecule insulin mimetics vanadyl acetylacetonate and Vanadium
(II) sulfate were utilized to induce bone healing. Vanadium compounds have already been shown
to promote bone growth, however the methods behind which are not fully understood, and these
compounds have also been shown to have cytotoxic effects at higher concentrations [29, 31, 32,
33]. The purpose of this research was to determine the optimal concentration and treatment time
of vanadyl acetylacetonate and Vanadium (II) sulfate to facilitate bone healing, and determine
whether or not these compounds utilize the same pathway as insulin to promote this growth.
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Methods

Cell Culture
MC3T3 cells were obtained from the O’Connor Lab (Rutgers New Jersey Medical
School, Newark, NJ). Cells were cultured in growth medium containing Minimum Essential
Growth Media MEM (Corning, Corning NY), 5% fetal bovine serum (FBS) (Atlanta Biologics),
1% penicillin/streptomycin (Corning, Corning NY), 1% glutamate (Corning, Corning NY), and
1% Sodium Pyruvate (Corning, Corning NY). When appropriate cells were also treated with
insulin (Invitrogen, Carlsbad CA), VSO4 (Sigma-Aldrich, St. Louis MO) and VAC (SigmaAldrich, St. Louis MO). The cells were incubated in a humidified environment of 5% CO2 at
37˚C and allowed to grow to 75%-80% confluency before being plated at various densities
depending on treatment. Cells were treated with controls of 1% ascorbic acid (50 mg/mL) and
1% insulin (50 mg/mL), or VAC and VSO4 at the following concentrations of 5 µM, 10 µM, 15
µM, 25 µM, 50 µM, and 100 µM. Insulin and Ascorbic Acid were utilized as controls because they
are used as common growth factors in bone development. In addition, insulin mimetics such as VAC
and VSO4 are believed to signal using a pathway like insulin to promote bone healing [23,31]
Alizarin Red Assay
In order to determine the level of calcium deposits within treated cell cultures, an
anthraquinone dye known as Alizarin Red, (ARS) was utilized. MC3T3 cells were seeded onto
24 well plates and allowed to reach confluency. Confluent cells were treated with differentiation
media (growth media containing 1% Ascorbic Acid) or differentiation media with 25 µM,
50µM, and 100 µM VSO4 or VAC and collected after 7, 10, 14, 17, and 21 days in triplicate.
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Post-treatment, MC3T3 cells were fixed with 4% formaldehyde for 15 minutes at room
temperature. After which, the cells were washed twice with diH2O, then 40 mM ARS was added
to each well and incubated at room temperature with gentle shaking for 20 minutes. Next, each
well was washed 4X with diH2O to remove any excessive dye and images were taken using a
phase contrast microscope (20X/0.30).
Calcium deposition was quantified by adding 10% acetic acid to each well and allowing
the plate to incubate at room temperature with gentle shaking for 30 minutes. The resulting acetic
acid and dye solutions in each well were transferred into individual centrifuge tubes, vortexed for
30 seconds, heated to 85˚C for 10 minutes, cooled with ice for 5 minutes, and then centrifuged at
13,500 g for 20 minutes. The supernatant was combined with 10% ammonium hydroxide,
transferred to a well plate, and read at 405nm using a 96-well Molecular Devices SpectraMAX
M5 spectrophotometer plate reader (Molecular Devices, San Jose CA).
Alcian Blue Assay
In order to determine the level of proteoglycan deposition an Alcian, (glacial), blue dye
was utilized. Treatments were prepared like those used in the Alizarin Red Assay. At each time
point, cells were fixed with 100% cold methanol for 5 minutes and then stained with 0.1 Alcian
blue in 0.1 M HCl overnight at 4 ˚C. Following the overnight incubation, cells were washed 3X
with 1X HBSS and digital images were taken using a phase contrast microscope (20X/0.30). The
cells were then extracted with room temperature 6M Guanidine-HCl and stored overnight at 4 ˚C
and then transferred to a 96-well plate and read at 595nm absorbance, using a 96-well Molecular
Devices SpectraMAX M5 spectrophotometer plate reader (Molecular Devices, San Jose CA).

Immunoblotting
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Protein expression of Akt and p-Akt were determined via immunoblotting in triplicate.
Cells were treated as previously stated, but time points included 6 hours, 24 hours, 4 days, 7 days,
10 days, and 14 days post-treatment. After each treatment, each well was washed once with
HBSS and the MC3T3 cells were lysed with mammalian protein extraction buffer (MPER buffer,
GE Healthcare, Chicago IL) and rocked gently for 5 minutes at room temperature. The resulting
lysate in each well was centrifuged at 13,500 g for 20 minutes. The supernatant containing the
clarified lysate was extracted and utilized for immunoblotting. Collected protein samples were
prepared for separation by being diluted 1:1 with 2X SDS Page Sample Buffer with 10%
mercaptothanol (GE Healthcare, Chicago IL). The samples were then heated to 70˚C and
separated utilizing 4-12% gradient NuPAGE Bis-Tris protein gels (Thermo Fisher, Waltham MA)
following manufacturer protocol. The running gel was transferred to a polyvinylidene membrane,
which was blocked from non-specific binding using SuperBlock (Thermo Fisher, Waltham MA)
overnight at 4˚C. Primary immunodetection of GAPDH (Cell Signaling Technology, Danvers
MA), Akt (Cell Signaling Technology, Danvers MA) and p-Akt (Cell Signaling Technology,
Danvers MA) was performed using mouse and rabbit derived antibodies. Secondary
immunodetection was performed using mouse and rabbit HRP-conjugated antibodies (R&D
systems) which corresponded with the respective primary antibodies. The bound antibodies were
detected via enhanced chemiluminescence detection following manufacturer protocol.
Chemiluminescent signals were detected and quantified using a Protein Simple Fluorchem E
MACHINE (Protein Simple, San Jose CA), and analyzed using the AlphaView software (Cell
Biosciences Inc., Santa Clara CA,Version 3.3.1.0)
MTT Assay:
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In order to measure cell proliferation, an MTT assay was utilized (Abcam, Cambridge
UK). MC3T3 cells were plated at varying seeding densities (4000 cells, 8000 cells, 16,000 cells,
32,000 cells, and 64,000 cells) using a 96-well plate. A seeding density of 8000 cells was found
to be the optimal and used for further analysis. The cells were treated with 1% insulin, 5 µM, 10
µM, 15 µM, 25 µM, 50 µM, and 100 µM of either VAC or VSO4 for a period of 24 hours. After
which an MTT reagent was prepared by dissolving 25 mg of MTT reagent powder (Abcam,
Cambridge UK), in 5 mL of HBSS in order to get a concentration of 5mg/mL. MTT reagent was
added to each well and allowed to incubate at 37˚C in for 2-4 hours. Following this incubation
DMSO was added to each well and the samples were incubated again at 37˚C in for 2-4 hours.
After this second incubation, absorbance was detected utilizing a 96-well Molecular Devices
SpectraMAX M5 spectrophotometer plate reader (Molecular Devices, San Jose CA) at an
absorbance of 590nm.

Results
Treatment with Vanadium (II) Sulfate (VSO4) and Vanadyl Acetylacetonate (VAC) Promote
Calcium Deposition
The effect VSO4 had on osteoblast calcium deposition was observed and analyzed
utilizing Alizarin Red Staining (ARS). MC3T3-E1 cells were treated with 0µM, 25µM, 50µM,
or 100µM VSO4, (each with 1% ascorbic acid at a concentration of 50µg/mL). The VSO4
treatments of 0µM, 25µM, 50µM, and 100µM were denoted differentiation media, low dose, mid
dose, and high dose, (DM, LD, MD, and HD), respectively. The cells were collected on days 7,
10, 14, 17, and 21.
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Calcium deposition in MC3T3-E1 cells were shown to be significantly different within different
treatment groups through one-way ANOVA (P<0.001). On day 7, all treatment groups displayed
a statistically significant difference to the control group according to the Holm-Sidak method
(P<0.050). Both the LD and MD had higher levels of calcium deposition than the control,
however only the LD and HD treatments had a P<0.001 when compared to the control group
according to the one-way ANOVA. The LD resulted in a calcium deposition increase of 10%
when compared to the DM, while the HD resulted in a calcium deposition decrease of 16% when
compared to the DM. VSO4 calcium deposition was significantly higher than controls on days 10
thru 17 (P<0.001) however higher doses reduced deposition. By day 17, the LD had the reached
peak calcium deposition, there was 44% increase in the levels of calcium deposition in LD group
when compared to the DM group. However, at the 21-day mark, the control group had
significantly higher levels of calcium deposition than that of the LD, (P<0.001). There was a
19% decrease in the levels of calcium deposition in the LD group when compared to the DM
group on the 21st day.
Cells were plated and treated in an identical matter with VAC. Calcium deposition in
MC3T3-E1 cells were shown to be significantly different within different treatment groups
through one-way ANOVA (P<0.001). On day 7, every treatment group, except for the MD
group, displayed a statistically significant difference to the control group of(P<0.050). Both the
LD and MD had higher levels of calcium deposition than the control, however only the HD
treatments had a (P<0.001) when compared to the control group according to the one-way
ANOVA. The LD resulted in a calcium deposition increase of 4% when compared to the DM,
while the HD resulted in a calcium deposition decrease of 14% when compared to the DM. On
day 10 VAC calcium deposition was significantly higher than controls (P<0.001) in the LD
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group, however in the HD group calcium deposition remained significantly lower (P<0.001). The
LD resulted in an 11% increase in levels of calcium deposition, while the HD group resulted in a
17% decrease. The LD and HD groups remained significantly different from controls (P<0.001)
on day 14 as well. By day 17, the LD was only significantly different from the DM group
according to the Holm-Sidak method (P<0.050). However, at the 21-day, the LD was no longer
significantly different from control group, but both the MD and HD had significantly lower
levels of calcium deposition when compared to the DM control (P<0.001). The MD resulted in a
29% decrease in the levels of calcium deposition when compared to the DM group and the 42%
decrease in levels of calcium deposition in the HD group when compared to the control.

Treatment with Vanadium (II) Sulfate (VSO4) and Vanadyl Acetylacetonate (VAC) Promote
Proteoglycan Deposition
MC3T3-E1 cells were treated identically to the ARS cells for Alcian Blue staining in
order to determine proteoglycan deposition, and similarly analyzed via one-way ANOVA. On
day 7, with the VSO4 treated cells, the Holm-Sidak test indicated that there was a significant
between each experimental group and the control group (P<0.050), however there was no
significant difference in proteoglycan deposition between the different treatment groups. LD
VSO4 significantly increased proteoglycan synthesis by 1.4-fold (P=0.35) when compared to
controls on Day 10 but higher doses reduced deposition. By the 14th day levels of proteoglycan
synthesis were still higher than that of the control group but had decreased from the 10th day. By
the 17th day the levels of proteoglycan deposition in the LD treatment group was significantly
lower than that of the control group, (a decrease of 16%). Cells were treated with VAC in an
identical matter to the cells treated with VSO4. On day 7, with the VAC treated group the Holm15

Sidak test indicated that there was a significant difference between the HD group and the control
group, as well as the HD group and the LD group (P<0.050). The HD resulted in a 13% decrease
in proteoglycan deposition when compared to the DM control group. On day 10, the HD was
shown to be significantly different to the DM control group, (P<0.001), also the LD and MD
groups were shown to be significantly different to the DM control group, (P<0.050). The LD
resulted in a 6% increase in proteoglycan deposition when compared to the control, the HD
resulted in a 31% decrease in proteoglycan deposition when compared to the control group. By
the 14th day, all VAC treatment groups were significantly different from the DM control group,
(P<0.001). The LD group resulted in an 8% increase in proteoglycan deposition when compared
to the control, while the HD resulted in a 38% decrease. By the 21st day levels of proteoglycan
synthesis had decreased in both the DM and LD groups, but levels of proteoglycan were still
significantly higher in both the DM and LD groups when compared to the MD and HD groups
(P<0.001).
Treatment with Vanadium (II) Sulfate (VSO4) and Vanadyl Acetylacetonate (VAC) Promotes
Cellular Proliferation
The effect of VSO4 had on osteoblast proliferation was analyzed utilizing an MTT assay.
Cells were treated with growth media, 1% insulin (at 50µg/mL) 0µM, 5µM, 10µM, 15µM
25µM, 50µM, or 100µM VSO4. Cells were collected after a 24-hour period. VSO4 treatment of
15µM-100µM had a significant positive effect on osteoblast proliferation when compared
controls (P<0.001). As the levels of VSO4 increased, so did the levels of cellular proliferation.
The largest increase occurred in the 100µM VSO4 group, which resulted in a 107% increase
when compared to the control. Cells were also plated in an identical matter and treated with
VAC. Every treatment group displayed a significant increase in cellular proliferation (P<0.001),
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with the exception of the 15µM group which displayed a significant decrease in cellular
proliferation (P<0.001). As both the higher and lower concentrations of VAC seem to have a
positive effect on cellular proliferation, this decrease is most likely due outside factors such as
pipetting error as opposed to an effect of then VAC treatments. Similarly, to the VSO4 treated
groups as the levels of VAC increased, so did the levels of cellular proliferation, with the largest
increase occurring at 100µM VAC, 63% compared to control.
Treatment with Vanadium (II) sulfate (VSO4) and Vanadyl Acetylacetonate (VAC) Effects p-Akt
Protein Expression
Expression of Akt and its activated form p-Akt, (the presence of which indicates the
utilization of the PI3K pathway in bone growth) was analyzed via Western Blotting. MC3T3-E1
cells were treated with 0µM, 25 µM, 50µM, or 100µM VSO4, (each with 1% ascorbic acid at a
concentration of 50µg/mL). The treatment groups were denoted control (DM control), low does
(LD), medium dose (MD), and high dose (HD) respectively. Cells were collected at the time
points of 6 hours, 24 hours, 4 days, 7 days, 10 days, and 14 days. Bands were normalized against
controls of GAPDH. VSO4 treatment at 6 hours showed no significant difference in both the
levels of Akt and p-Akt between the treatment groups and the controls according to the HolmSidak method. By the 24 hour mark, all VSO4 treatment groups still showed no significant
difference in levels of Akt when compared to the control, however, there was a significant
difference in levels of p-Akt expression in the MD and HD groups (P<0.001). The MD resulted
in a 34% increase in levels p-Akt expression, while the HD resulted in a 60% increase. There
remained no significant difference in levels of Akt expression between the experimental groups
and the control group until the 7th day, at which point there was a significant difference between
each the LD, MD, and HD groups and the control (P<0.050). The LD, MD, and HD resulted in
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an 18%, 35%, and 37% decrease in levels of Akt expression when compared to the DM control
respectively. In addition, the levels of p-Akt expression were significantly different from the
control (P<0.001). The MD resulted in a 48% increase in the levels of p-Akt expression and the
HD resulted in a 38% increase in the levels of p-Akt expression. On day 10, the MD was
considered significantly different from the DM control, (P<0.001), in terms of Akt expression,
also both the LD and HD groups were considered significantly different from the DM control,
(P<0.050). The MD resulted in a 55% decrease in the levels of Akt expression. Levels of p-Akt
expression were significantly different in each of the VSO4 treatment groups when compared to
the control (P<0.001). The LD, MD, and HD resulted in a 37%, 85%, and 58% increase in levels
of p-Akt expression respectively. On day 14, both the MD and HD groups were significantly
different from the control, (P<0.001), as well as the LD (P<0.050). The MD resulted in a 46%
decrease in levels of p-AKT expression, and the HD resulted in a 44% decrease. The ratios of pAkt over Akt expression within these VSO4 treated groups were also calculated and compared to
the DM control. After a period of 6 hours, there was no significant difference between the DM
controls and each of the VSO4 treatment groups. At the 24 hour mark, one-way ANOVA
revealed that the LD and MD treatment groups were significantly different when compared to the
DM control (P<0.050), the HD group was also significantly different from the control (P<0.001).
The HD group resulted in a 51.4% increase in levels of p-Akt/Akt when compared to the DM
control. On day 4, only the HD group was significantly different from the control (P<0.001). The
HD resulted in a 213.3% increase in levels of p-Akt/Akt when compared to the DM control. By
day 7, both the MD and HD groups were significantly different from the DM control (P<0.001).
The MD and HD groups resulted in a 124.9% and 120% increase in levels of p-Akt/Akt when
compared to the DM control respectively. By day 10 each the LD, MD, and HD groups were
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significantly different from the DM control (P<0.001). The LD, MD, and HD groups lead to a
98.2%, 308%, and 227.4% increase in levels of p-Akt/Akt when compared to the DM control
respectively. On day 14, the LD group was considered significantly different from the DM
control (P<0.050), the MD and HD groups were also significantly different from the control
(P<0.001). The MD and HD groups resulted in a 147.3% and a 171.2% increase in levels of pAkt/Akt when compared to the DM control respectively. Cells were treated with VAC in an
identical matter to the cells treated with VSO4. Similarly, to VSO4 treated cells, VAC treatment
at 6 hours showed no significant difference in both the levels of Akt and p-Akt between the
treatment groups and the control according to the Holm-Sidak method. After 24 hours, all VAC
treatment groups still showed no significant difference in levels of Akt when compared to the
control, however there was a significant difference in the levels of p-Akt expression between the
MD and the DM control (P<0.050); also one way ANOVA revealed that there was a significant
difference in levels of p-Akt expression in the HD group (P<0.001) when compared to the
control. The HD resulted in a 44% increase in levels of p-Akt expression. On day 4 there was a
significant difference in the levels of Akt expression in the MD and HD groups when compared
to the control, (P<0.050). The MD and HD resulted in a 44% and 48% decrease in levels of Akt
expression respectively. The levels of p-Akt expression were significantly different in the HD
treatment group when compared to the control (P<0.001), and the MD groups was considered
significantly different as well (P<0.050).The MD resulted in an 88% increase in the levels of pAkt, the HD resulted in a 26% increase in the levels of p-Akt expression. On day 7 only the HD
was considered significantly different from the DM control (P<0.050) in levels of Akt
expression. The HD resulted in a 103% decrease in the levels of AKT expression. Levels of pAkt expression were significantly different in the MD and HD VAC treatment groups when
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compared to the control, (P<0.001). The MD and HD resulted in a 36%, and 35% increase in
levels of p-Akt expression respectively. By the 10th day, only the HD VAC treatment group was
significantly different from the control, (P<0.050). The HD group resulted in a 58% decrease in
levels of Akt expression. The MD was significantly different from the DM control in levels of pAkt expression, (P<0.001), as well as both the LD and HD treatment groups (P<0.050). The LD,
MD, and HD resulted in an increase 30%, 188%, and 42% in levels of p-Akt expression
respectively. On day 14, each of the VAC treatment groups were significantly different from the
control (P<0.050). Treatment with LD, MD, and HD resulted in a 34%, 47%, and 47% decrease
in levels of p-AKT expression respectively. The MD and HD groups were shown to be
significantly different in levels of p-Akt expression when compared to the DM control
(P<0.050). The MD resulted in an 18% decrease in levels of p-Akt, while the HD resulted in a
17% decrease. The ratio of p-Akt over Akt expression within these VAC treated groups were
also calculated and compared to the DM control. At both the 6 hour and 24 hour marks, there
was no significant different in the levels of p-Akt/Akt when comparing each of the VAC
treatment groups to the DM control. By day 4, the MD group was considered significantly
different from the DM control (P<0.050), the HD groups was also considered significantly
different from the control (P<0.001). The HD group resulted in a 258% increase in levels of pAkt/Akt when compared to the DM control .On day 7 the LD was significantly different from the
DM control (P<0.050), as were the MD and HD groups (P<0.001). The MD and HD groups
resulted in a 134% and a 173.5% increase in levels of p-Akt/Akt when compared to the DM
control respectively. By day 10, the LD, MD, and HD groups were all significantly different
from the DM control (P<0.001). The LD, MD, and HD resulted in a 130.2%, 515.8%, and
218.2% increase in levels of p-Akt/Akt when compared to the DM control. On day 14, each of
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the treatment groups were significantly different from the control (P<0.050). The LD, MD, and
HD groups resulted in a 52.2%, 49.3%, and 53.1% increase in levels of p-Akt/Akt when
compared to the DM control respectively.
Discussion
Recent studies have shown that VAC can stimulate bone growth in vivo and in vitro,
which suggests that VAC may have potential as a therapeutic agent in fracture healing [29, 34].
These same studies revealed that intramedullary injection of VAC at fracture sites increased the
percentage of bone, cartilage, as well as mechanical properties when compared to controls in
non-diabetic rat models [29, 34]. Despite these findings, the mechanisms behind which small
molecule insulin mimetics, (such as VAC, ZnCl2, and VSO4), facilitate bone healing remain
poorly understood. Recent data suggests that insulin mimetics facilitate bone healing by affecting
three major factors; enhancing chondrogenesis and osteoblastogenesis, as well as reducing the
proliferation of osteoclasts [35, 36, 37].
Vanadium compounds have already been shown to activate important elements in the
insulin signaling pathway at the cellular level, such as activation of extracellular signal‐regulated
kinase (ERK1/2) [38]. This results in an increase of vascular endothelial growth factor VEGF,
increasing levels of angiogenesis [34, 39]. In addition, vanadium appears to increase levels of
tyrosine phosphorylation of insulin receptor substrate‐1 (IRS‐1) [40] and activation of
phosphatidylinositol 3‐kinase (PI3K) [40], factors utilized in the insulin pathway that help induce
bone healing. Previous studies have shown that VAC activates similar signaling cascades as
insulin, [41, 42, 43], suggesting that it and other insulin mimetics may be useful in facilitating
bone healing. Despite this information, the mechanisms behind which VAC aid in bone healing
are not fully understood, and to our knowledge, the effects of VSO4 on bone healing have yet to
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be evaluated. Here we showed that both VAC and VSO4 enhanced MC3T3-E1 osteoblast
differentiation, facilitated the production of calcium and proteoglycan, and appeared to induce
the utilization Akt/p-Akt in MC3T3-E1 cells similarly to insulin [25].
Our data demonstrates an increase in osteoblast proliferation after treatment with insulin
mimetic, which coincides with the results of a study conducted by Ippolito et al. that showed an
increase in bone production after local injection at a fracture site that enhanced the overall
mechanical properties of the bone [29]. Our study also demonstrated that VAC and VSO4 treated
groups induced increased production of calcium and proteoglycan. These findings concur with a
study conducted by Sanchez-Gonzalez et al. in which bis(maltolato)oxovanadium(iv) was
utilized in order to correct decreased levels of calcium deposition and increased levels OPN
mRNA expression in the femurs of diabetic rat models [45]. Normally, OPN binds to the surface
of osteoclasts and allows them to attach to mineralized bone, therefore decreasing bone density.
Treatment of diabetic rat models with bis(maltolato)oxovanadium(iv) increases levels of calcium
deposition and decreases OPN mRNA expression which causes bone density levels to be similar
to non-diabetic controls [45]. This data and the data from our own study suggests that vanadium
compounds are capable of not just inducing increased osteoblast proliferation, but also
promoting production of calcium and proteoglycan for the mineralization of bone in the
formation of the hard callus. Our data illustrates that calcium and proteoglycan deposition was
highest in MC3T3-E1 cells in both the ascorbic acid controls and the lowest doses of VAC and
VSO4 after a period of 21 days. This suggests that while higher doses of vanadium compounds
appear to increase cellular proliferation similar to controls, their viability can be diminished.
Insulin phosphorylates IRS1 and IRS2, activating of PI3K. Once PI3K is activated, Akt
can be activated via phosphorylation, forming p-Akt [25]. The role of p-Akt is to phosphorylate
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the transcription factor FOXO1, inappropriate activation of which causes hyperglycemia. Insulin
mimetics like VAC and VSO4 should be capable of inducing a similar signaling cascade with the
PI3K pathway [25, 26]. Our data demonstrates that both Akt and p-Akt are utilized during
MC3T3-E1 proliferation in VAC and VSO4 treated cells. These results coincide with studies
conducted by Gao et al., Norozui et al., and Nimmanon et al. In the Gao et al study, it was
demonstrated that vanadate (V2O5) induces hypoxia-inducible factor 1 (HIF-1) activity through
expression of HIF-1α, increases VEGF expression in DU145 human prostate carcinoma cells.
The signaling pathway involved in vanadate-induced HIF-1 alpha and VEGF expression were
also studied and it was found that PI3K/Akt signaling was required for HIF-1 and VEGF
expression induced by vanadate [46]. Not only was it required, but vanadate also induced PI3K
activity and Akt phosphorylation in a dose- and time-dependent manner [46]. In the Norozui
study another insulin mimetic, zinc sulfate (ZnSO4), was utilized to evaluate the insulin-like
effects of zinc on the cell signaling molecules Akt, tyrosine, GSK-3β , ERK1/2, p38, and SHP-2,
as well as glucose oxidation in mouse (C2C12) and human skeletal muscle cells. ZnSO4
independently led to the phosphorylation of these proteins in both mouse (C2C12) and human
skeletal muscle cells [47]. In addition, zinc induced the phosphorylation of Akt within in both
mouse (C2C12) and human skeletal muscle cells when cells were exposed to the same
concentration ZnSO4 as insulin [47]. The Nimmanon study focused families of transport
proteins: such as ZIP channels (SLC39A), which control levels of zinc within a cell. ZIP
channels, specifically ZIP7 (of 14), increase cytosolic zinc levels by importing zinc into cells or
releasing zinc from intracellular stores like the endoplasmic reticulum (ER) [48]. The study
demonstrated the role of ZIP7-mediated zinc release in MCF-7 cells, (a human derived breast
cancer cell line) in driving major pathways, such as MAPK PI3K-AKT, and mTOR. Zinc
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treatment of ZIP7-transfected cells MCF-7 cells increased ZIP7-mediated zinc release and lead
to the phosphorylation/activation of AKT within the cells. This study also showed that ZIP7
induced zinc release was able to activate both PI3K and mTOR [48]. These studies and our data
suggests that vanadium compounds and other insulin mimetics are capable of inducing cellular
proliferation via activation of the PI3K pathway similarly to insulin [49]. Our study indicates that
over time levels of p-Akt seem to exceed levels of Akt in levels of expression in both VAC and
VSO4 treatment groups, indicating the phosphorylation/activation of Akt to form p-Akt.
In summary this data demonstrates that treatment with of MC3T3-E1 cells with VAC and
VSO4 enhances both osteoblast proliferation and function overtime. In addition, increased
expression of p-Akt overtime suggests that the positive effects seen on osteoblastogenesis are
mediated by the PI3K pathway, similarly to insulin. In the future, other key mediators in the
PI3K pathway such as FOXO1, VEGF, and mTOR must be studied in order to determine if the
entire pathway is being utilized in order to facilitate bone healing.
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Figure 1: Treatment with VSO4 promotes Calcium deposition in differentiated
MC3T3-E1 cells. Cells were collected after days 7, 10, 14, 17, and 21. Treatment
groups included MC3T3-E1 cells grown in differentiation medium, (DM) consisting
of growth media supplemented with 50 mg/mL ascorbic acid (AA) control or the
indicated amount of VSO4 supplemented with 50 mg/mL ascorbic acid. Error bars
represent mean±SD. */#/^denote statistically significant differences between
treatment groups where appropriate; corresponding p values are noted.
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Figure 2: Treatment with VAC promotes Calcium deposition in differentiated
MC3T3-E1 cells. Cells were collected after days 7, 10, 14, 17, and 21. Treatment
groups included MC3T3-E1 cells grown in differentiation medium, (DM), consisting
of growth media supplemented with 50 mg/mL ascorbic acid control, (AA), or the
indicated amount of VAC supplemented with 50 mg/mL ascorbic acid. Error bars
represent mean±SD. */#/^denote statistically significant differences between
treatment groups where appropriate; corresponding p values are noted.
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Figure 3: Treatment with VSO4 promotes Proteoglycan deposition in differentiated
MC3T3-E1 cells. Cells were collected after days 7, 10, 14, 17, and 21. Treatment
groups included MC3T3-E1 cells grown in differentiation medium, (DM), consisting
of growth media supplemented with 50 mg/mL ascorbic acid control, (AA), or the
indicated amount of VSO4 supplemented with 50 mg/mL ascorbic acid. Error bars
represent mean±SD. */#/^denote statistically significant differences between
treatment groups where appropriate; corresponding p values are noted.
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Figure 4: Treatment with VAC promotes Proteoglycan deposition in differentiated
MC3T3-E1 cells. Cells were collected after days 7, 10, 14, 17, and 21. Treatment
groups included MC3T3-E1 cells grown in differentiation medium, (DM), consisting
of growth media supplemented with 50 mg/mL ascorbic acid control, (AA), or the
indicated amount of VAC supplemented with 50 mg/mL ascorbic acid. Error bars
represent mean±SD. */#/^/+ denote statistically significant differences between
treatment groups where appropriate; corresponding p values are noted.
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Figure 5: Treatment with VSO4 promotes cellular proliferation in differentiated
MC3T3-E1 cells. Cells were collected after 24 hours. Treatment groups included
MC3T3-E1 cells grown in differentiation medium (DM) as a control, DM with 50
mg/mL insulin or the indicated amount of VSO4. Error bars represent mean±SD.
*/#/^/+ denote statistically significant differences between treatment groups where
appropriate; corresponding p values are noted.
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Figure 6: Treatment with VAC promotes cellular proliferation in differentiated
MC3T3-E1 cells. Cells were collected after 24 hours. Treatment groups included
MC3T3-E1 cells grown in differentiation medium (DM) as a control, DM with 50
mg/mL insulin or the indicated amount of VSO4. Error bars represent mean±SD.
*/#/^/+ denote statistically significant differences between treatment groups where
appropriate; corresponding p values are noted.
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Figure 7: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 6 hours. Treatment groups included MC3T3-E1 cells grown in
differentiation medium, (DM) consisting of growth media supplemented with 50
mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented with 50
mg/mL ascorbic acid. Error bars represent mean±SD. A.) Western blot images Akt
and p-Akt protein band expression for each treatment group. B.) Bar graph of a
side by side comparison of levels of Akt expression vs. levels of p-Akt expression. C.)
Bar graph displaying the ratio of levels of p-Akt/Akt expression
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Figure 8: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 24 hours. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression
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Figure 9: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 4 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 10: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 7 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 11: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 10 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.

41

Figure 12: Treatment with VSO4 promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 14 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VSO4 supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 13: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 6hrs. Treatment groups included MC3T3-E1 cells grown in
differentiation medium, (DM) consisting of growth media supplemented with 50
mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented with
50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote statistically
significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 14: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 24hrs. Treatment groups included MC3T3-E1 cells grown in
differentiation medium, (DM) consisting of growth media supplemented with 50
mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented with
50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote statistically
significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 15: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 4 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 16: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 7 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.

46

Figure 17: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 10 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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Figure 18: Treatment with VAC promotes activation of Akt in differentiated
MC3T3-E1 cells. Akt and p-Akt were normalized to GAPDH, (not shown). Cells
were collected after 14 days. Treatment groups included MC3T3-E1 cells grown
in differentiation medium, (DM) consisting of growth media supplemented with
50 mg/mL ascorbic acid, (AA), or the indicated amount of VAC supplemented
with 50 mg/mL ascorbic acid. Error bars represent mean±SD. */# denote
statistically significant differences between treatment groups where appropriate;
corresponding p values are noted. A.) Western blot images Akt and p-Akt
protein band expression for each treatment group. B.) Bar graph of a side by
side comparison of levels of Akt expression vs. levels of p-Akt expression. C.) Bar
graph displaying the ratio of levels of p-Akt/Akt expression.
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